Get the full picture
Sign in to uncover key details.
EvolveImmune Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Connecticut, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
23 Business Park Dr, Branford, Connectic...Phone Number
(203) 208-6584Website
www.evolveimmune.comRevenue
$15 MillionIndustry
About EvolveImmune Therapeutics
EvolveImmune Therapeutics is pioneering a pipeline of unique trispecific T cell engagers with integrated CD2 costimulation, addressing the challenges of cancer cell resistance to current immunotherapies. The company's lead drug candidate, EVOLVE104, is set to enter clinical trials in 2025. EvolveImmune is committed to improving the lives of cancer patients and their families through innovative therapeutic solutions. They have also partnered with Abbvie to develop additional therapeutics leveraging the power of costimulation.Explore more
EvolveImmune Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to EvolveImmune Therapeutics
Compare insights from companies similar to EvolveImmune Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
EvolveImmune Therapeutics
$15M
11-50
Private
$37M
2020
LM
Louis MatisSenior Adviser To CEO At EvolveImmune Therapeutics
EvolveImmune Therapeutics Tech Stack
A closer look at the technologies used by EvolveImmune Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding EvolveImmune Therapeutics
Sign Up For FreeTo access detailed company insights
EvolveImmune Therapeutics is pioneering a pipeline of unique trispecific T cell engagers with integrated CD2 costimulation, addressing the challenges of cancer cell resistance to current immunotherapies. The company's lead drug candidate, EVOLVE104, is set to enter clinical trials in 2025. EvolveImmune is committed to improving the lives of cancer... Read More
